Search Results
Your search for ,EMD matches 362 pages
Showing 351 - 362Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma
Immunotherapy marches on! One of the latest frontiers for checkpoint inhibitors is the treatment of Merkel cell carcinoma, a rare but aggressive type of cancer. First-line therapy with pembrolizumab (Keytruda)—an anti–PD-1 (programmed cell death protein 1) inhibitor—achieved an objective response...
Optimizing Outcomes in Pancreatic Cancer
Evidence has long supported a volume-outcome relationship for surgical resection of pancreatic cancer, yet surgery alone is not enough to prolong survival in patients with localized disease. James L. Abbruzzese, MD, of Duke University and Duke Cancer Institute, Durham, North Carolina, discussed his ...
Studies Explore Role of Bevacizumab in Combination Therapies for Glioblastoma
At the 2013 ASCO Annual Meeting, studies evaluating the addition of bevacizumab (Avastin) to standard therapy in newly diagnosed glioblastoma multiforme patients did not meet their primary endpoints. When paired with irinotecan, however, bevacizumab showed activity in MGMT-unmethylated tumors....
Three 'Game-Changers' in the Treatment of Melanoma
There have been three “game-changers” in the treatment of melanoma, Mark R. Albertini, MD, Associate Professor of Medicine at the University of Wisconsin in Madison, contended at the Best of ASCO Chicago meeting. The first, he explained, was the recognition of different genetic driver...
All-RAS Testing in Metastatic Colorectal Cancer: Just the First Step
Now that clinicians know to “think beyond KRAS” in metastatic colorectal cancer—and test for all RAS mutations, not just those in exon 2—it seems this is still not sufficient for selecting the best drugs. At the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, a proffered paper ...
Expert Point of View: Mary L. Disis, MD
Study discussant Mary L. Disis, MD, Professor of Medicine and Associate Dean of Translational Science at the University of Washington, Seattle, commented that the response rate, approaching 20%, is “in the ballpark” of those observed in melanoma, lung cancer, and renal cancer. She pointed out that...
Pancreatic Cancer: Latest Drug Development Hits and Misses
Targeting one of the deadliest cancers and seeking to fill an unmet need, drug development in pancreatic cancer is an area of high interest. This was certainly the case at the 2015 Gastrointestinal Cancers Symposium, where results were impressive for some novel agents but disappointing for several...
What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?
An analysis of Gynecologic Oncology Group (GOG) studies recently reported in the Journal of Clinical Oncology by Tewari and colleagues and reviewed in this issue of The ASCO Post showed a survival benefit of intraperitoneal chemotherapy vs intravenous chemotherapy over long-term follow-up in women...
CheckMate 067: Dual Checkpoint Blockade Proves Effective in Advanced Melanoma
In advanced melanoma, combination treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) more than doubled the median progression-free survival time over ipilimumab alone in the CheckMate 067 trial. That said, single-agent nivolumab proved almost as powerful in patients expressing the programmed ...
Ovarian Cancer Trialists Forming Work Group to Standardize Definition of Pathologic Complete Response
Ovarian cancer clinical trialists are forming a working group to develop a standard definition of pathologic complete response in ovarian cancer treated with neoadjuvant chemotherapy. Such agreement within the field potentially would enable the U.S. Food and Drug Administration (FDA) to consider...
ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma
A randomized phase III trial among patients with previously untreated melanoma found that initial therapy with nivolumab (Opdivo) alone more than doubled the median progression-free survival compared with ipilimumab (Yervoy) alone (6.9 vs 2.9 months), and the benefit was even greater when the two...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
